Vanda Pharmaceuticals (VNDA)
5.43
+0.09 (1.69%)
Upcoming Events
Latest Headlines
EU grants Vanda's imsidolimab first orphan status for rare skin disease
August 24, 2026 7:04 AM - StreetInsider
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
August 24, 2026 7:00 AM - PR NewsWire
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
August 22, 2026 3:17 PM - PR NewsWire
Form SCHEDULE 13G Vanda Pharmaceuticals Filed by: MILLENNIUM MANAGEMENT LLC
August 19, 2026 6:32 PM - SEC Filing
This biotech stock offers a buying opportunity: B. Riley
August 15, 2026 10:00 AM - StreetInsider
Form SCHEDULE 13G Vanda Pharmaceuticals Filed by: AQR CAPITAL MANAGEMENT LLC
August 13, 2026 9:23 AM - SEC Filing
Vanda Pharmaceuticals (VNDA) PT Lowered to $12 at B.Riley
August 10, 2026 8:18 AM - StreetInsider
Vanda Pharmaceuticals (VNDA) PT Lowered to $20 at H.C. Wainwright
August 10, 2026 6:49 AM - StreetInsider
Form 10-Q Vanda Pharmaceuticals For: Jun 30
August 6, 2026 7:39 AM - SEC Filing
Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 44c; Offers Guidance
August 5, 2026 4:05 PM - StreetInsider
Form 8-K Vanda Pharmaceuticals For: Aug 05
August 5, 2026 4:05 PM - SEC Filing
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 5, 2026 4:01 PM - PR NewsWire
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
July 29, 2026 4:32 PM - PR NewsWire
EMA backs orphan drug status for Vanda's imsidolimab in rare skin disease
July 16, 2026 4:30 PM - StreetInsider
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
July 16, 2026 4:30 PM - PR NewsWire
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
July 15, 2026 4:30 PM - PR NewsWire
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
July 10, 2026 4:30 PM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
July 9, 2026 6:51 AM - StreetInsider
FDA grants Vanda rare pediatric disease tag for CMT2S therapy
July 7, 2026 4:31 PM - StreetInsider
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
July 7, 2026 4:30 PM - PR NewsWire
Full Article List
